Page 77 - Zai Lab News Today

ARGX earnings call for the period ending March 31, 2021.

1 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today reported financial results for the first quarter 2021 and provided a business update. “We’ve had a strong start to 2021 with the acceptance for review of the BLA and J-MAA for efgartigimod in gMG by the regulatory agencies in the U.S. and Japan. The submissions in China and the EU are on track and we...

5 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson Neilson’s Stake Value: $7,262,000 Percent of Kerr Neilson’s 13F Portfolio: 0.16% Number of Hedge Fund Holders: 30 Zai Lab Limited (NASDAQ: ZLAB) is a Chinese biopharmaceutical company that specialises in discovering, developing, licencing, and commercializing therapeutics for treatment of oncology, autoimmune, and infectious diseases. Early this year, the company announced its financial results for the second half and...

Drunk or Dead Windows, VR game This game was made on 48-hour non stop Christmas VR hackathon by 8 indiedevs. It will be a classical one room single position shooter.The setting is wild west bar, but with waves of zombies coming in. According to storyline, you are caught by zombie apocalypse caused by virus, which affects only sober people. So in order to stay uninfected, you have to drink from time to time. Drinking has its own mechanics. If you are close to sober you shoot accurately. When you...

May 10, 2021 10:50am Yizhe Wang arrives two months after LianBio struck its latest partnerships and added Yi Larson as chief financial officer to the team. (Freeman Zhou / Unsplash) As LianBio strikes more deals to bring new drugs to China, the company is installing a new CEO: Yizhe Wang, Ph.D., who will arrive next Monday after leading the team that brought Eli Lilly’s COVID-19 antibody, bamlanivimab, to an emergency nod. Wang fills a vacuum left by LianBio’s founding CEO Bing ...

BeiGene, Astellas and CANbridge made our news this week. (Google) BeiGenes first-quarter sales jumped 104% year over year to $106 million as it started to benefit from demand surging on new national reimbursement coverage. The Chinese biotech also won a local go-ahead for a PARP inhibitor to challenge incumbents Lynparza and Zejula. Astellas walked away from a muscle disease pact with Cytokinetics after a midstage trial flop. And more. BeiGene more than doubled product sales year over year to...

Operator Good afternoon, everyone and welcome to Deciphera Pharmaceuticals First Quarter 2021 Financial Results Conference call. Todays call is being recorded. At this time, I would like to hand the conference over to Jen Robinson, Vice President of Investor Relations. You may begin. Jen Robinson -- Vice President of Investor Relations Thank you, Tolanda. Welcome and thank you for joining us today to discuss Decipheras first quarter 2021 financial results. Im Jen Robinson, Vice President, Inve...

Changed on 03/05/2021 The State’s public services have to convert to using digital technology... But to do so, they need tools adapted to their needs. This is the objective of AI Lab, which aims to introduce data science and artificial intelligence into administrative organisations to offer new work possibilities for employees and new functionalities for users. ©NicoElNino - stock.adobe.com Support French administrative organisations in their digital transition and ...

Erdafitinib (Janssen Research and Development). The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.  Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a muc...

Cd86), were down-regulated in Mettl3-deficient cells (Fig. 1G), suggesting that METTL3 has a critical function in controlling the innate immune response of Raw 264.7 macrophages. To further confirm the biological role of the m 6A modification in macrophages, Mettl3 conditional KO (CKO) mice were generated by crossing Mettl3 flox/flox mice with mice expressing Cre recombinase under the control of lysozyme 2 promoter ( Lyzm-Cre). We have documented the loss of both the METTL3 protein and the o...